US FDA to establish timeframes for drug companies to implement new safety labelling
This article was originally published in SRA
The US Food and Drug Administration is seeking feedback on its plans to establish general timeframes within which new safety labelling for approved prescription drugs should be disseminated and reflected on a product's packaging1.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.